| pubmed-article:17013922 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:17013922 | lifeskim:mentions | umls-concept:C0030567 | lld:lifeskim |
| pubmed-article:17013922 | lifeskim:mentions | umls-concept:C0684224 | lld:lifeskim |
| pubmed-article:17013922 | lifeskim:mentions | umls-concept:C0031979 | lld:lifeskim |
| pubmed-article:17013922 | lifeskim:mentions | umls-concept:C2603343 | lld:lifeskim |
| pubmed-article:17013922 | lifeskim:mentions | umls-concept:C1875723 | lld:lifeskim |
| pubmed-article:17013922 | lifeskim:mentions | umls-concept:C1301732 | lld:lifeskim |
| pubmed-article:17013922 | pubmed:issue | 12 | lld:pubmed |
| pubmed-article:17013922 | pubmed:dateCreated | 2006-12-27 | lld:pubmed |
| pubmed-article:17013922 | pubmed:abstractText | Piribedil is a D2 dopamine agonist, which has been shown to improve symptoms of Parkinson's disease (PD) when combined with L-dopa. The objective of this study was to compare the efficacy of piribedil monotherapy to placebo in patients with early PD over a 7-month period. Four hundred and five early PD patients were randomized (double-blind) to piribedil (150-300 mg/day) or placebo. L-dopa open-label supplementation was permitted. Unified Parkinson Disease Rating Scale part III (UPDRS III) score as the last observation on monotherapy over 7 months was the primary outcome measure. Secondary outcomes were proportion of responders (UPDRS III improvement > 30%), patients remaining on monotherapy after 7 months, UPDRS III subscores, and UPDRS II. UPDRS III improved on piribedil (-4.9 points) versus a worsening on placebo (2.6 points; estimated effect = 7.26 points; 95% CI = 5.38-9.14; P < 0.0001). The proportion of responders was significantly higher for piribedil (42%) than for placebo (14%) (OR = 4.69; 95% CI = 2.82-7.80; P < 0.001). Piribedil significantly improved several UPDRS III subscores. UPDRS II improved on piribedil by -1.2 points, while it deteriorated by 1.5 points on placebo (estimated effect = 2.71; 95% CI = 1.8-3.62; P < 0.0001). The proportion of patients remaining on monotherapy after 7 months was greater in the piribedil group (OR = 3.72; 95% CI = 2.26-6.11; P < 0.001). Safety was consistent with that reported for other dopamine agonists, gastrointestinal side effects being the most common (22% of patients in piribedil group vs. 14% on placebo). Piribedil is effective and safe as early PD therapy. | lld:pubmed |
| pubmed-article:17013922 | pubmed:language | eng | lld:pubmed |
| pubmed-article:17013922 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17013922 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:17013922 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17013922 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17013922 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17013922 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:17013922 | pubmed:month | Dec | lld:pubmed |
| pubmed-article:17013922 | pubmed:issn | 0885-3185 | lld:pubmed |
| pubmed-article:17013922 | pubmed:author | pubmed-author:RascolOlivier... | lld:pubmed |
| pubmed-article:17013922 | pubmed:author | pubmed-author:SennStephenS | lld:pubmed |
| pubmed-article:17013922 | pubmed:author | pubmed-author:LeesAndrewA | lld:pubmed |
| pubmed-article:17013922 | pubmed:author | pubmed-author:DuboisBrunoB | lld:pubmed |
| pubmed-article:17013922 | pubmed:author | pubmed-author:Del... | lld:pubmed |
| pubmed-article:17013922 | pubmed:author | pubmed-author:CaldasAlexand... | lld:pubmed |
| pubmed-article:17013922 | pubmed:author | pubmed-author:Parkinson... | lld:pubmed |
| pubmed-article:17013922 | pubmed:copyrightInfo | Copyright 2006 Movement Disorder Society. | lld:pubmed |
| pubmed-article:17013922 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:17013922 | pubmed:volume | 21 | lld:pubmed |
| pubmed-article:17013922 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:17013922 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:17013922 | pubmed:pagination | 2110-5 | lld:pubmed |
| pubmed-article:17013922 | pubmed:meshHeading | pubmed-meshheading:17013922... | lld:pubmed |
| pubmed-article:17013922 | pubmed:meshHeading | pubmed-meshheading:17013922... | lld:pubmed |
| pubmed-article:17013922 | pubmed:meshHeading | pubmed-meshheading:17013922... | lld:pubmed |
| pubmed-article:17013922 | pubmed:meshHeading | pubmed-meshheading:17013922... | lld:pubmed |
| pubmed-article:17013922 | pubmed:meshHeading | pubmed-meshheading:17013922... | lld:pubmed |
| pubmed-article:17013922 | pubmed:meshHeading | pubmed-meshheading:17013922... | lld:pubmed |
| pubmed-article:17013922 | pubmed:meshHeading | pubmed-meshheading:17013922... | lld:pubmed |
| pubmed-article:17013922 | pubmed:meshHeading | pubmed-meshheading:17013922... | lld:pubmed |
| pubmed-article:17013922 | pubmed:meshHeading | pubmed-meshheading:17013922... | lld:pubmed |
| pubmed-article:17013922 | pubmed:meshHeading | pubmed-meshheading:17013922... | lld:pubmed |
| pubmed-article:17013922 | pubmed:meshHeading | pubmed-meshheading:17013922... | lld:pubmed |
| pubmed-article:17013922 | pubmed:meshHeading | pubmed-meshheading:17013922... | lld:pubmed |
| pubmed-article:17013922 | pubmed:meshHeading | pubmed-meshheading:17013922... | lld:pubmed |
| pubmed-article:17013922 | pubmed:meshHeading | pubmed-meshheading:17013922... | lld:pubmed |
| pubmed-article:17013922 | pubmed:meshHeading | pubmed-meshheading:17013922... | lld:pubmed |
| pubmed-article:17013922 | pubmed:meshHeading | pubmed-meshheading:17013922... | lld:pubmed |
| pubmed-article:17013922 | pubmed:meshHeading | pubmed-meshheading:17013922... | lld:pubmed |
| pubmed-article:17013922 | pubmed:year | 2006 | lld:pubmed |
| pubmed-article:17013922 | pubmed:articleTitle | Early piribedil monotherapy of Parkinson's disease: A planned seven-month report of the REGAIN study. | lld:pubmed |
| pubmed-article:17013922 | pubmed:affiliation | INSERM U455, Clinical Investigation Center and Departments of Clinical Pharmacology and Neurosciences, Faculté de Médecine, Toulouse, France. rascol@cict.fr | lld:pubmed |
| pubmed-article:17013922 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:17013922 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:17013922 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:17013922 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:17013922 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:17013922 | pubmed:publicationType | Multicenter Study | lld:pubmed |
